1. Home
  2. ALAR vs SKYE Comparison

ALAR vs SKYE Comparison

Compare ALAR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$7.61

Market Cap

57.1M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.09

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
SKYE
Founded
2013
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.1M
44.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ALAR
SKYE
Price
$7.61
$1.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$27.00
$14.75
AVG Volume (30 Days)
91.6K
244.8K
Earning Date
11-26-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$36,305,000.00
N/A
Revenue This Year
$31.17
N/A
Revenue Next Year
$30.14
N/A
P/E Ratio
$47.06
N/A
Revenue Growth
15.03
N/A
52 Week Low
$5.45
$1.09
52 Week High
$18.00
$5.75

Technical Indicators

Market Signals
Indicator
ALAR
SKYE
Relative Strength Index (RSI) 18.61 34.37
Support Level $7.72 $1.10
Resistance Level $9.35 $1.27
Average True Range (ATR) 0.49 0.09
MACD -0.08 0.02
Stochastic Oscillator 0.23 0.00

Price Performance

Historical Comparison
ALAR
SKYE

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: